Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBBD Chemotherapy for Primary CNS Lymphoma
NCT00074178Phase 2Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2000
- Primary completion
- Jul 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, cyclophosphamide and etoposide phosphate in primary central nervous system lymphoma (PCNSL), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Survival at 5 years and Toxicity. Started Jan 2000; status: completed.
02
Drugs
methotrexatecyclophosphamideetoposide phosphate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00074178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074178.